Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection‐Site Reactions
JGH Open · 2026-04 · 10 (4)
DOI: 10.1002/jgh3.70407 ↗Kurz gefasst
Fachartikel in der Zeitschrift JGH Open, online erschienen am 21.04.2026. Verfasst von Makoto Furuya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology IBD Center, Tsujinaka Hospital Kashiwanoha Chiba Japan. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Aims The subcutaneous (SC) formulation of vedolizumab is available as an alternative to the intravenous (IV) formulation in patients with ulcerative colitis (UC). However, data from Asian patients are limited, and the clinical course of injection‐site reactions (ISRs) remains unclear. This study evaluated the efficacy and safety of switching from IV to SC vedolizumab in Japanese patients with UC, focusing on ISRs.
Methods
This retrospective study included patients who switched from IV to SC vedolizumab. The primary outcomes were the incidence and clinical course of ISRs. The secondary outcomes included adverse events other than ISRs, disease activity, remission rates, and treatment persistence.
Results
In total, 48 patients were included. The median fecal calprotectin levels remained stable from baseline to 12 months after switching (46.0 vs. 46.0 μg/g), with the fecal calprotectin remission rate remaining stable (41/45, 91% vs. 39/45, 87%). The persistence rate of SC vedolizumab was 98%, and the persistence rate without additional therapy was 94%. ISRs occurred in 29 patients (60%), most frequently within 3–6 months, with a median duration of 4 months. More than half of ISRs improved or resolved by 12 months, and only 11 patients (23%) experienced persistent ISRs. No adverse events other than ISRs were considered likely or probably related to SC vedolizumab.
Conclusions
In Asian patients with UC, disease activity was maintained after switching from IV to SC vedolizumab. Although ISRs were common after switching, most were self‐limiting. Therefore, switching back to IV formulation solely for ISR management should be cautiously considered.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology IBD Center, Tsujinaka Hospital Kashiwanoha Chiba Japan.
- Department of Gastroenterology Graduate School of Medicine, Chiba University Chiba Japan.
ORCID-Profile: Ken Takeuchi
Zitieren
APA
Furuya, M., Yoza, K., Yonezawa, T., & Takeuchi, K. (2026). Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection‐Site Reactions. JGH Open, 10(4). https://doi.org/10.1002/jgh3.70407
Vancouver
Furuya M, Yoza K, Yonezawa T, Takeuchi K. Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection‐Site Reactions. JGH Open. 2026;10(4). doi:10.1002/jgh3.70407
BibTeX
@article{Furuya2026,
author = {Furuya, Makoto and Yoza, Kiichiro and Yonezawa, Takeshi and Takeuchi, Ken},
title = {Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection‐Site Reactions},
journal = {JGH Open},
year = {2026},
volume = {10},
number = {4},
doi = {10.1002/jgh3.70407}
}
EUVIMED